Rajat Thawani on “Combination Immunotherapy clinical trials in NSCLC”
Rajat Thawani, Assistant Professor, University of Chicago Hematology/Oncology, shared a post on X:
“It was an honor to present a talk on “Combination Immunotherapy clinical trials in NSCLC” at the Ontario Institute for Cancer Research for OICR Mondays.
In summary, I believe a good second line NSCLC option would be able to compete with anti PD-1/PD-L1 options.
Otherwise, we will be combining drugs to anti PD-1 agents (+/- chemotherapy) to improve ORR. We will have many options to choose from — dual checkpoints, ADCs, vaccines, cytokines and targeted therapies! How do we choose the best partner for the patient — Use AI for ‘precision immunotherapy?”
Radiological artificial intelligence – predicting personalized immunotherapy outcomes in lung cancer
Authors: Laila C. Roisman, Waleed Kian, Alaa Anoze, Vered Fuchs, Maria Spector, Roee Steiner, Levi Kassel, Gilad Rechnitzer, Iris Fried, Nir Peled and Naama R. Bogot.
Source: Rajat Thawani/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023